Resistant viral variants in cellular reservoirs of human immunodeficiency virus infection

Clinical Microbiology and Infection

Volumn 16, Issue 10, 2010, Pages 1518-1524

  Turriziani, O ^a   Andreoni, M ^b   Antonelli, G ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Cellular reservoirs; Drug resistance; HIV; HIV DNA; Review

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS DNA; VIRUS RNA;

ANTIVIRAL RESISTANCE; BLOOD ANALYSIS; CELL COMPARTMENTALIZATION; DNA DETERMINATION; DNA SEQUENCE; DRUG RESPONSE; DRUG TREATMENT FAILURE; ERADICATION THERAPY; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTRACELLULAR SPACE; LONG TERM CARE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PERMEABILITY BARRIER; PRIORITY JOURNAL; REVIEW; RNA ANALYSIS; RNA SEQUENCE; VIRUS CARRIER; VIRUS DETECTION; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77957063611     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2010.03329.x     Document Type: Review

References (57)

1. Finzi D, Hermankova M, Pierson T. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
2. Chun TW, Engel D, Berrey MM. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998, 95:8869-8873.
3. Pierson T, McArthur J, Siliciano RF. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 2000, 18:665-708.
4. Alexaki A, Liu Y, Wigdahl B. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res 2008, 6:388-400.
5. Chun TW, Davey RT, Ostrowski M. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med 2000, 6:757-761.
6. Almodóvar S, Del C, Colón M. HIV-1 infection of monocytes is directly related to the success of HAART. Virology 2007, 369:35-46.
7. Gibellini D, Borderi M, De Grignis E. HIV-1 DNA load analysis in peripheral blood lymphocytes and monocytes from naive and HAART-treated individuals. J Infect 2008, 56:219-225.
8. Delobel P, Sandres-Sauné K, Cazabat M. Persistence of distinct HIV-1 populations in blood monocytes and naive and memory CD4 T cells during prolonged suppressive HAART. AIDS 2005, 19:1739-1750.
9. Dahl V, Josefsson L, Palmer S. HIV reservoirs, latency, and reactivation: prospects for eradication. Antiviral Res 2010, 85:286-294.
10. Persaud D, Pierson T, Ruff C. A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. J Clin Invest 2000, 105:995-1003.
11. Devereux HL, Youle M, Johnson MA. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999, 13:F123-F127.
12. Deeks SG, Wrin T, Liegler T. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001, 344:472-480.
13. Noë A, Plum J, Verhofstede C. The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance. J Antimicrob Chemother 2005, 55:410-412.
14. Wang YM, Dyer WB, Wokman C. Molecular evidence for drug-induced compartmentalization of HIV-1 quasispecies in a patient with periodic changes to HAART. AIDS 2000, 14:2265-2272.
15. Paolucci S, Baldanti F, Campanini G. Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients. J Med Virol 2001, 65:207-217.
16. Ruff CT, Ray SC, Kwon P. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol 2002, 76:9481-9492.
17. Lambotte O, Chaix ML, Gubler B. The lymphocytes HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS 2004, 18:1147-1158.
18. Verhofstede C, Noe A, Demecheleer E. Drug-resistant variants that evolve during non suppressive therapy persist in HIV-1 infected peripheral blood mononuclear cells after long-term highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2004, 35:473-483.
19. Vicenti I, Razzolini F, Saladini F. Use of peripheral blood DNA for genotype antiretroviral resistance testing in drug-naive HIV-infected subjects. Clin Infect Dis 2007, 44:1657-1661.
20. Turriziani O, Bucci M, Stano A. Genotypic resistance of archived and circulating viral strains in the blood of treated HIV-infected individuals. J Acquir Immune Defic Syndr 2007, 44:518-524.
21. Bon I, Gibellini D, Borderi M. Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients. J Clin Virol 2007, 38:313-320.
22. Bon I, Alessandrini F, Borderi M. Analysis of HIV-1 drug-resistant variants in plasma and peripheral blood mononuclear cells from untreated individuals: implications for clinical management. New Microbiol 2007, 30:313-317.
23. d'Ettorre G, Zaffiri L, Ceccarelli G. The role of HIV-DNA testing in clinical practice. New Microbiol 2010, 33:1-11.
24. Kabamba-Mukadi B, Duquenne A, Henrivaux P. HIV-1 proviral resistance mutations: usefulness in clinical practice. HIV Med 2010, 11:483-492.
25. Wang YM, Dyer WB, Workman C. Drug resistance and viral evolution in plasma and peripheral blood cells during structured treatment interruption (STI) and non-interrupted HAART. Curr HIV Res 2007, 5:235-250.
26. Ghosn J, Pellegrin I, Goujard C. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006, 20:159-170.
27. Venturi G, Romano L, Carli T. Divergent distribution of HIV-1 drug-resistant variants on and off antiretroviral therapy. Antivir Ther 2002, 7:245-250.
28. Saracino A, Gianotti N, Marangi M. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART. J Med Virol 2008, 80:1695-1706.
29. Sarmati L, Nicastri E, Uccella I. Drug-associated resistance mutations in plasma and in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing. J Clin Microbiol 2003, 41:1760-1762.
30. Delaugerre C, Chaix ML, Blanche S. Perinatal acquisition of drug-resistant HIV-1 infection:mechanisms and long-term outcome. Retrovirology 2009, 6:85-97.
31. Kieffer TL, Finucane MM, Nettles RE. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 2004, 189:1452-1465.
32. Martinez-Picado J, DePasquale MP, Kartsonis N. Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc Natl Acad Sci USA 2000, 97:10948-10953.
33. Diaz RS, Accetturi CA, Sucupira MC. Emergence of resistance mutations preceding virologic failure in patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2008, 49:111-113.
34. Palmisano L, Galluzzo CM, Giuliano M. The importance of testing genotypic resistance in proviral DNA of patients fully responding to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009, 51:233-234.
35. Potter SJ, Dwyer DE, Saksena NK. Differential cellular distribution of HIV-1 drug resistance in vivo: evidence for infection of CD8+ T cells during HAART. Virology 2003, 305:339-352.
36. Turriziani O, Boni A, Falasca F. Mutational resistance pattern of HIV type 1 in CD14(+) monocytes, CD4(+) T cells, and plasma from treated patients. AIDS Res Hum Retroviruses 2010, 26:625-634.
37. Moon YJ, Zhang S, Morris ME. Real time quantitative polymerase chain reaction for BCRP, MDR1 and MRP1 mRNA levels in lymphocytes and monocytes. Acta Haematol 2007, 118:169-175.
38. Borrow P, Shaw GM, Wei X. Antiviral pressure exerted by HIV-1 specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997, 3:205-211.
39. Moore CB, John M, James IR. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002, 296:1439-1443.
40. Sonza S, Mutimer HP, Oelrichs R. Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy. AIDS 2001, 15:17-22.
41. Zhu T, Muthui D, Holte S. Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J Virol 2002, 76:707-716.
42. Coombs RW, Reichelderfer PS, Landay AL. Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS 2003, 17:455-480.
43. Kotler DP, Reka S, Borcich A, Cronin WJ. Detection, localization, and quantitation of HIV-associated antigens in intestinal biopsies from patients with HIV. Am J Pathol 1991, 139:823-830.
44. Marras D, Bruggeman LA, Gao F. Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat Med 2002, 8:522-526.
45. Antinori A, Perno CF, Giancola ML. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis 2005, 41:1787-1793.
46. Poles MA, Elliott J, Vingerhoets J. Despite high concordance, distinct mutational and phenotypic drug resistance profiles in human immunodeficiency virus type 1 RNA are observed in gastrointestinal mucosal biopsy specimens and peripheral blood mononuclear cells compared with plasma. J Infect Dis 2001, 183:143-148.
47. Canestri A, Lescure FX, Jaureguiberry S. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 2010, 50:773-778.
48. Bergroth T, Ekici H, Gisslén M. Difference in drug resistance patterns between minor HIV-1 populations in cerebrospinal fluid and plasma. HIV Med 2009, 10:111-115.
49. Kiessling AA, Fitzgerald LM, Zhang D. Human immunodeficiency virus in semen arises from a genetically distinct virus reservoir. AIDS Res Hum Retroviruses 1998, 14(suppl 1):S33-S41.
50. Leruez-Ville M, Dulioust E, Costabliola D. Decrease in HIV-1 seminal shedding in men receiving highly active antiretroviral therapy: an 18 month longitudinal study (ANRS EP012). AIDS 2002, 16:486-488.
51. Ghosn J, Viard JP, Katlama C. Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV-infected men. AIDS 2004, 18:447-457.
52. Pillai SK, Good B, Pond SK. Semen-specific genetic characteristics of human immunodeficiency virus type 1 env. J Virol 2005, 79:1734-1742.
53. Coombs RW, Lockhart D, Ross SO. Lower genitourinary tract sources of seminal HIV. J Acquir Immune Defic Syndr 2006, 41:430-438.
54. Liuzzi G, Chirianni A, Zaccarelli M. Differences between semen and plasma of nucleoside reverse transcriptase resistance mutations in HIV-infected patients, using a rapid assay. In Vivo 2004, 18:509-512.
55. Smith DM, Wong JK, Shao H. Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission. J Infect Dis 2007, 196:356-360.
56. Di Stefano M, Favia A, Monno L. Intracellular and cell-free (infectious) HIV-1 in rectal mucosa. J Med Virol 2001, 65:637-643.
57. Monno L, Punzi G, Scarabaggio T. Mutational patterns of paired blood and rectal biopsies in HIV-infected patients on HAART. J Med Virol 2003, 70:1-9.